Cognition and Fatigue in Multiple Sclerosis: Potential Effects of Medications with Central Nervous System Activity

By Oken, Barry S.; Flegal, Kristin et al. | Journal of Rehabilitation Research & Development, January-February 2006 | Go to article overview

Cognition and Fatigue in Multiple Sclerosis: Potential Effects of Medications with Central Nervous System Activity


Oken, Barry S., Flegal, Kristin, Zajdel, Daniel, Kishiyama, Shirley S., Lovera, Jesus, Bagert, Bridget, Bourdette, Dennis N., Journal of Rehabilitation Research & Development


Abstract--To evaluate the potential effects of medications with central nervous system (CNS) activity on cognitive function and fatigue in multiple sclerosis (MS), we performed a retrospective analysis of medication use among 70 subjects with MS who were participating in a clinical trial for evaluation of the effects of yoga and exercise programs on cognition and fatigue. Among these MS subjects, 74% were taking at least one potentially CNS-active medication. These 70 subjects were divided into two groups: those taking at least one CNS-active medication (n = 52) and those not on any medications with potential CNS activity (n = 18). We compared assessments of cognitive function and fatigue using an analysis of covariance. MS subjects on CNS-active medication had greater impairment on measures of processing speed, sustained attention, and fatigue than those not on these medications. While these findings do not establish a causal relationship between medication use and cognitive impairment and fatigue, the data indicate that researchers need to control for use of CNS-active medications when conducting studies of cognitive impairment and fatigue in MS subjects.

Key words: alertness, attention, attentional shifting, central nervous system agents, cognition, divided attention, fatigue, multiple sclerosis, processing speed, reaction time, sustained attention.

INTRODUCTION

Many cognitive function changes occur with multiple sclerosis (MS) [1-2]. These cognitive changes may involve almost any area of cognition, although deficits in attention, including speed of processing, are particularly common [2]. People with attentional system deficits from MS, or other conditions such as frontal lobe lesions or aging, may have memory deficits secondary to the attentional problems [3-5]. These attentional systems, along with the interrelated alertness systems, are more affected by drugs than other aspects of cognitive function. This is especially true for drugs with direct effects on neurotransmitters that are involved in the relatively nonspecific cortical projection systems (acetylcholine, norepinephrine, dopamine, serotonin, and histamine) or widely distributed cortical neurotransmitters (gamma-aminobutyric acid). Thus, a confounding issue in the study of cognition in MS is the frequent presence of medications with central nervous system (CNS) activity.

Many CNS-active drugs are known to affect cognitive function [6-7]. People who may already experience some cognitive impairment such as MS patients, as well as elderly people and patients with traumatic brain injury, are at higher risk than most people for additional cognitive dysfunction from medications [6]. Among these drugs with negative effects on cognitive function, antiepileptic drugs (AEDs) may be the most clinically studied. All AEDs have some negative effects on cognitive function as assessed by blinded placebo-controlled studies in healthy subjects, although some relative differences exist among the AEDs in the magnitude of these effects [8]. One point of potential relevance to MS is that subjective complaints of cognitive dysfunction from AEDs often exceed deficits identified by more formal neuropsychological testing, although cognitive tests sensitive to the effects of AEDs may require greater effort [9-10]. Many other drugs used by people with MS may negatively affect cognitive function as assessed by controlled trials in healthy control subjects, patient groups, or animals. This list includes tricyclic antidepressants, anticholinergics, first generation antihistamines, baclofen, beta-blockers, amantadine, selective serotonin reuptake inhibitors (SSRIs), and benzodiazepines [6-7,11-21]. On the other hand, methylphenidate and related drugs (modafinil) improve some cognitive functions in healthy subjects [11,22-23].

In many studies of MS and cognition, including some clinical trials, relatively little attention has been paid to the issue of CNS-active drugs [24]. …

The rest of this article is only available to active members of Questia

Sign up now for a free, 1-day trial and receive full access to:

  • Questia's entire collection
  • Automatic bibliography creation
  • More helpful research tools like notes, citations, and highlights
  • Ad-free environment

Already a member? Log in now.

Notes for this article

Add a new note
If you are trying to select text to create highlights or citations, remember that you must now click or tap on the first word, and then click or tap on the last word.
One moment ...
Default project is now your active project.
Project items

Items saved from this article

This article has been saved
Highlights (0)
Some of your highlights are legacy items.

Highlights saved before July 30, 2012 will not be displayed on their respective source pages.

You can easily re-create the highlights by opening the book page or article, selecting the text, and clicking “Highlight.”

Citations (0)
Some of your citations are legacy items.

Any citation created before July 30, 2012 will labeled as a “Cited page.” New citations will be saved as cited passages, pages or articles.

We also added the ability to view new citations from your projects or the book or article where you created them.

Notes (0)
Bookmarks (0)

You have no saved items from this article

Project items include:
  • Saved book/article
  • Highlights
  • Quotes/citations
  • Notes
  • Bookmarks
Notes
Cite this article

Cited article

Style
Citations are available only to our active members.
Sign up now to cite pages or passages in MLA, APA and Chicago citation styles.

(Einhorn, 1992, p. 25)

(Einhorn 25)

1

1. Lois J. Einhorn, Abraham Lincoln, the Orator: Penetrating the Lincoln Legend (Westport, CT: Greenwood Press, 1992), 25, http://www.questia.com/read/27419298.

Cited article

Cognition and Fatigue in Multiple Sclerosis: Potential Effects of Medications with Central Nervous System Activity
Settings

Settings

Typeface
Text size Smaller Larger Reset View mode
Search within

Search within this article

Look up

Look up a word

  • Dictionary
  • Thesaurus
Please submit a word or phrase above.
Print this page

Print this page

Why can't I print more than one page at a time?

Full screen

matching results for page

Cited passage

Style
Citations are available only to our active members.
Sign up now to cite pages or passages in MLA, APA and Chicago citation styles.

"Portraying himself as an honest, ordinary person helped Lincoln identify with his audiences." (Einhorn, 1992, p. 25).

"Portraying himself as an honest, ordinary person helped Lincoln identify with his audiences." (Einhorn 25)

"Portraying himself as an honest, ordinary person helped Lincoln identify with his audiences."1

1. Lois J. Einhorn, Abraham Lincoln, the Orator: Penetrating the Lincoln Legend (Westport, CT: Greenwood Press, 1992), 25, http://www.questia.com/read/27419298.

Cited passage

Thanks for trying Questia!

Please continue trying out our research tools, but please note, full functionality is available only to our active members.

Your work will be lost once you leave this Web page.

For full access in an ad-free environment, sign up now for a FREE, 1-day trial.

Already a member? Log in now.